Latest gout Stories
LONDON, May 25, 2011 /PRNewswire/ -- Ardea Biosciences, Inc.
EAST HANOVER, N.J., May 25, 2011 /PRNewswire/ -- Novartis announced today results of two pivotal Phase III trials in patients with severe gouty arthritis, showing that ACZ885 (canakinumab) provided superior pain relief and reduced the risk of suffering new attacks by up to 68% compared to an injectable steroid (triamcinolone acetonide, TA) used to treat gouty arthritis attacks(1,2).
HAYWARD, Calif., May 19, 2011 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced today that it has initiated a Phase 2 clinical trial of arhalofenate (MBX-102), its product candidate for the management of hyperuricemia in patients with gout. This randomized, double-blind, placebo-controlled study will evaluate the safety and urate-lowering activity of 400 and 600...
CLEVELAND, May 17, 2011 /PRNewswire/ -- A new survey from the nonprofit Gout & Uric Acid Education Society (GUAES) highlights an alarming awareness gap among Americans regarding the risk factors for gout, a chronic, potentially disabling form of arthritis which now affects an estimated 8.3 million Americans.(1) Among the survey findings are that only one in 10 Americans correctly cited cardiovascular disease as a risk factor for gout, while only one in three Americans correctly reported...
SAN DIEGO, May 9, 2011 /PRNewswire/ -- Ardea Biosciences, Inc.
EAST BRUNSWICK, N.J., May 4, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc.
The incidence of gout is on the rise and duel energy CT has the potential to allow non-invasive diagnosis of the disease.
EAST BRUNSWICK, N.J., April 28, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that three abstracts will be presented at the European League Against Rheumatism (EULAR) 2011 Annual Congress.
The Concept Laboratories arthritis and gout treatment story is actually three amazing stories in one.
SAN DIEGO, April 25, 2011 /PRNewswire/ -- Ardea Biosciences, Inc.
- A person in a secondary role, specifically the second most important character (after the protagonist).